Riddhishkumar Shah

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Angela Alistar, Bonny Morris, Rodwige Desnoyer et al. · The Lancet Oncology · 2017 · 228 citations

Medicine, Oncology, Pharmacology +11

Population‐based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetes

John N. Harvey, Kashif Rizvi, L Craney et al. · Diabetic Medicine · 2001 · 52 citations

Medicine, Internal Medicine, Diabetology +7

<i>TNF</i>, <i>LTA</i> and <i>TGFB1</i> genotype distributions among acute graft‐<i>vs</i>‐host disease subsets after HLA‐matched unrelated hematopoietic stem cell transplantation: a pilot study

Riddhishkumar Shah, S. Selby, Brian H. Yokley et al. · Tissue Antigens · 2009 · 15 citations · Full text

Life Sciences, Hematology, Immunology +17

S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC

D. Ferry, Lucinda Billingham, Hugh Jarrett et al. · Thorax · 2011 · 13 citations · Full text

Medicine, Oncology, Pharmacology +14